# Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease

> clinical trial · VERIFIED · 2026-06-11

Status: TEMPORARILY_NOT_AVAILABLE · Sponsor: David Williams · Condition: Sickle Cell Disease

- Company: David Williams
- Sector: gene-therapy
- Primary source: https://clinicaltrials.gov/study/NCT07640815

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.